You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華海藥業(600521.SH)臨近午盤收盤拉昇漲停 獲允許生產輝瑞Paxlovid成分原料藥和製劑
格隆匯 03-17 12:41
格隆匯3月17日丨日內瓦藥品專利池(Medicines PatentPool, MPP)組織宣佈,已與35家藥企簽署協議,允許其生產輝瑞新款口服藥Paxlovid成分之一奈瑪特韋(nirmatrelvir)原料藥或製劑。包括5家中國企業,其中就有華海藥業。華海藥業獲允許可同時生產原料藥和製劑。根據協議條款,全球獲得授權許可的合格仿製藥企業將能夠向95個國家/地區提供Paxlovid的組合療法,覆蓋全球約53%的人口,包括撒哈拉以南非洲的所有低收入和中低收入國家和一些中高收入國家,以及過去五年中從中低收入狀態轉變為中高收入狀態的國家。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account